Rexulti (REX-ul-TE) can help treat agitation that might accompany Alzheimer's disease, the most common form of dementia. The ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Analysts have suggested that approval for AAD could swell sales of Rexulti by $500 million to $1 billion, a big step up for a drug which currently makes around $1.4 billion in annual sales.

The cost of drugs a PDP covers may change throughout the year. This may be due to the different phases of Part D coverage. In 2025, these include: The MPPP is a new payment option in the ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

The list price of Rexulti is $1,419 per month. However, people can pay much less through a prescription drug plan (PDP), also known as Medicare Part D. According to the manufacturers of the drug ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Alzheimer’s agitation represents a large market where Rexulti would be Auvelity’s only competitor. But the Axsome drug has the opportunity to offer a safety edge. Rexulti’s label carries a ...

Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Let your healthcare professionals (e.g. doctor or pharmacist) know that you are ...